Related Experiment Videos

[BNP-guided therapy optimizes the timing of discharge and the medium term risk stratification in patients admitted

Roberto Valle1, Nadia Aspromonte, Emanuele Carbonieri

  • 1Centro per lo scompenso cardiaco, Unità operativa complessa di Cardiologia, Ospedale civile, San Donà di Piave. robertovalle@libero.it

Monaldi Archives for Chest Disease = Archivio Monaldi Per Le Malattie Del Torace
|March 26, 2008
PubMed

Insights

Plasma brain natriuretic peptide (BNP) levels can guide heart failure (HF) treatment and predict prognosis. Higher BNP levels at discharge indicate a greater risk of cardiac events and death in HF patients.

Area of Science:

  • Cardiology
  • Biomarkers
  • Heart Failure Management

Background:

  • Congestive heart failure (HF) is a leading cause of hospitalization with high readmission rates.
  • Neurohormonal activation, indicated by plasma brain natriuretic peptide (BNP), correlates with HF severity and patient outcomes.

Purpose of the Study:

  • To assess if plasma BNP levels can guide drug treatment in HF patients post-discharge.
  • To determine if BNP levels can predict medium-term prognosis in HF patients after hospitalization.

Main Methods:

  • 200 HF patients were evaluated, with echocardiography and plasma BNP levels measured on admission and after initial treatment.
  • Patients were categorized into low BNP responders and high BNP non-responders based on a 240 pg/ml cutoff and/or a 30% reduction in BNP levels.
  • Clinical variables, including NYHA class and ejection fraction, were analyzed alongside BNP levels.

Main Results:

  • High BNP levels (>240 pg/mL) indicated clinical instability requiring intervention, while low levels allowed for earlier discharge.
  • The high BNP group (42%) experienced significantly more cardiac events than the low BNP group (10%) during a 3-month follow-up.
  • Plasma BNP values >500 pg/mL identified a subgroup at high risk of death.

Conclusions:

  • BNP testing is crucial for risk stratification in hospitalized HF patients to guide management.
  • An aggressive treatment and follow-up strategy is warranted for HF patients with high BNP levels or minimal BNP changes post-admission.
  • Changes in plasma BNP levels at discharge significantly correlate with subsequent cardiac events.
Abstract

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Mitral Regurgitation IV: Nursing Management01:28

Mitral Regurgitation IV: Nursing Management

Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...